Abbott Laboratories(NYSE) ABT

Abbott Laboratories makes tools that help people track their health. It creates heart devices, baby formula, and rapid medical tests. These products help doctors and families manage diseases every day.

Products for Every Stage of Life

• Medical Devices: Heart rhythm, vascular, and diabetes care tools; earned $11.4 billion in net sales in the six-month period ended June 30, 2026.
• Diagnostic Products: Laboratory and rapid tests for diseases like cancer or respiratory viruses; generated $5.3 billion in net sales in the six-month period ended June 30, 2026.
• Nutritional Products: Health formulas for infants and adults; recorded $4.2 billion in net sales in the six-month period ended June 30, 2026.
• Established Pharmaceutical Products: Branded generic medicines sold in emerging markets; produced $2.9 billion in net sales in the six-month period ended June 30, 2026.

Scaling Through Strategic Acquisitions

• Acquired Exact Sciences Corporation on March 23, 2026, for approximately $20.6 billion to establish a presence in the cancer diagnostics market.
• Integrated the Cologuard and Oncotype DX brands into a new Cancer Diagnostics category within the diagnostic testing segment.
• Secured the CE Mark, a European safety certification, for the Libre Duo dual glucose-ketone biowearable sensor in May 2026.
• Repaid approximately $2.8 billion of debt assumed through the Exact Sciences acquisition by June 30, 2026.

A Multi-Industry Healthcare Leader

Abbott uses a balanced business model to provide everything from pediatric nutrition to high-tech heart implants. The company maintains a deep presence in emerging markets where it sells generic medicines for chronic conditions like hypertension and migraine.

Key Results by the Numbers

• Net sales reached $23.8 billion in the six-month period ended June 30, 2026, up 10.5% year over year.
• Diagnostic Products sales rose 22.4% in the six-month period ended June 30, 2026, excluding the impact of foreign exchange.
• Research and development spending was $1.7 billion in the six-month period ended June 30, 2026, up 15.1% year over year.
• Continuous glucose monitoring (CGM) systems, which track sugar levels for people with diabetes, generated $4.1 billion in sales in the six-month period ended June 30, 2026.
• Market cap was $158.2 billion in Q2 2026, a 33.2% decrease from $236.7 billion in Q2 2025.

Building a Healthier Future

Abbott has evolved into a global healthcare leader by focusing on life-changing technology and essential nutrition. Recent entries into cancer diagnostics and continuous glucose monitoring strengthen its position in high-growth medical markets.